Kailera Therapeutics, Inc. (KLRA) Institutional Shareholders
Kailera Therapeutics, Inc. (KLRA) is currently reported in institutional portfolios tracked by InsiderSet based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026. The institutional investors covered on this page collectively reported approximately $2.49B in KLRA holdings during the latest filing period.
Bain Capital Investors Llc is currently the largest disclosed institutional shareholder of KLRA tracked by InsiderSet, reporting ownership valued at approximately $578.41M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $336.86M, representing an estimated loss of -41.76% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 80% of the total disclosed KLRA value among the investors covered in this analysis. Major shareholders include Bain Capital Investors Llc, Bain Capital Life Sciences Investors, Llc, Rtw Investments, Lp, and several other long-term asset managers with concentrated positions in Kailera Therapeutics, Inc. (KLRA).
This page ranks the largest institutional KLRA shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
Institutional Holders
94
Total Reported Value
$2.49B
Largest Holder
Bain Capital Investors Llc
Largest Position
$578.41M
Insider Transactions (90d)
0
Latest Filing Quarter
Q2 2026
New Institutional Positions
96
Funds Exiting Positions
0
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Bain Capital Investors Llc | 12.01% | 26,255,581 | $578,410,449 | $336,859,104 | -$241,551,345 | -41.76% | |
| Bain Capital Life Sciences Investors, Llc | 29.58% | 22,583,268 | $497,509,394 | $289,743,328 | -$207,766,066 | -41.76% | |
| Rtw Investments, Lp | 2.03% | 10,776,820 | $237,413,345 | $138,266,601 | -$99,146,744 | -41.76% | |
| Canada Pension Plan Investment Board | 0.09% | 7,304,688 | $160,922,277 | $93,719,147 | -$67,203,130 | -41.76% | |
| Atlas Venture Life Science Advisors, Llc | 12.93% | 5,171,282 | $113,923,342 | $66,347,548 | -$47,575,794 | -41.76% | |
| Fmr Llc | 0.00% | 3,970,865 | $87,478,156 | $50,946,198 | -$36,531,958 | -41.76% | |
| Blackrock, Inc. | 0.00% | 3,928,604 | $86,547,146 | $50,403,989 | -$36,143,157 | -41.76% | |
| Price T Rowe Associates Inc | 0.01% | 3,534,410 | $77,864,000 | $45,346,480 | -$32,517,520 | -41.76% | |
| Citadel Advisors Llc | 0.04% | 3,240,787 | $71,394,538 | $41,579,297 | -$29,815,241 | -41.76% | |
| Adage Capital Partners Gp, L.L.C. | 0.10% | 3,208,286 | $70,678,541 | $41,162,309 | -$29,516,232 | -41.76% | |
| Wellington Management Group Llp | 0.01% | 2,919,110 | $64,307,994 | $37,452,181 | -$26,855,813 | -41.76% | |
| Royalty Pharma Sub-Manager, Llc | 22.36% | 2,455,357 | $54,091,515 | $31,502,230 | -$22,589,285 | -41.76% | |
| Siren, L.L.C. | 0.99% | 2,214,286 | $48,780,721 | $28,409,289 | -$20,371,432 | -41.76% | |
| Vanguard Capital Management Llc | 0.00% | 1,693,958 | $37,317,895 | $21,733,481 | -$15,584,414 | -41.76% | |
| Vanguard Portfolio Management Llc | 0.00% | 1,652,507 | $36,404,729 | $21,201,665 | -$15,203,064 | -41.76% | |
| Geode Capital Management, Llc | 0.00% | 1,133,115 | $24,968,475 | $14,537,865 | -$10,430,610 | -41.78% | |
| Frazier Life Sciences Management, L.P. | 0.53% | 1,100,000 | $24,233,000 | $14,113,000 | -$10,120,000 | -41.76% | |
| Trails Edge Capital Partners, Lp | 3.44% | 984,786 | $21,694,836 | $12,634,804 | -$9,060,032 | -41.76% | |
| Ubs Group Ag | 0.00% | 972,683 | $21,428,206 | $12,479,523 | -$8,948,683 | -41.76% | |
| Ameriprise Financial Inc | 0.00% | 821,331 | $18,093,970 | $10,537,677 | -$7,556,293 | -41.76% | |
| Deep Track Capital, Lp | 0.23% | 700,000 | $15,421,000 | $8,981,000 | -$6,440,000 | -41.76% | |
| Eventide Asset Management, Llc | 0.18% | 616,720 | $13,586,342 | $7,912,518 | -$5,673,824 | -41.76% | |
| Vestal Point Capital, Lp | 0.30% | 575,000 | $12,667,250 | $7,377,250 | -$5,290,000 | -41.76% | |
| Cormorant Asset Management, Lp | 0.62% | 550,000 | $12,116,500 | $7,056,500 | -$5,060,000 | -41.76% | |
| Federated Hermes, Inc. | 0.01% | 434,069 | $9,562,540 | $5,569,105 | -$3,993,435 | -41.76% | |
| Goldman Sachs Group Inc | 0.00% | 421,034 | $9,275,379 | $5,401,866 | -$3,873,513 | -41.76% | |
| Charles Schwab Investment Management Inc | 0.00% | 362,910 | $7,994,907 | $4,656,135 | -$3,338,772 | -41.76% | |
| Northern Trust Corp | 0.00% | 354,431 | $7,808,115 | $4,547,350 | -$3,260,765 | -41.76% | |
| Vanguard Fiduciary Trust Co | 0.00% | 290,128 | $6,391,520 | $3,722,342 | -$2,669,178 | -41.76% | |
| Seven Grand Managers, Llc | 0.16% | 175,000 | $3,855,250 | $2,245,250 | -$1,610,000 | -41.76% | |
| Balyasny Asset Management L.P. | 0.01% | 154,838 | $3,411,081 | $1,986,572 | -$1,424,509 | -41.76% | |
| Exchange Traded Concepts, Llc | 0.02% | 152,501 | $3,359,597 | $1,956,588 | -$1,403,009 | -41.76% | |
| Manufacturers Life Insurance Company, The | 0.00% | 149,817 | $3,300,469 | $1,922,152 | -$1,378,317 | -41.76% | |
| Td Asset Management Inc | 0.00% | 147,698 | $3,253,787 | $1,894,965 | -$1,358,822 | -41.76% | |
| A16Z Capital Management, L.L.C. | 0.02% | 140,000 | $3,084,200 | $1,796,200 | -$1,288,000 | -41.76% | |
| Aberdeen Group Plc | 0.00% | 140,000 | $3,084,200 | $1,796,200 | -$1,288,000 | -41.76% | |
| Nantahala Capital Management, Llc | 0.19% | 140,000 | $3,084,200 | $1,796,200 | -$1,288,000 | -41.76% | |
| Bank Of New York Mellon Corp | 0.00% | 138,399 | $3,048,930 | $1,775,659 | -$1,273,271 | -41.76% | |
| Alps Advisors Inc | 0.01% | 131,000 | $2,885,930 | $1,680,730 | -$1,205,200 | -41.76% | |
| Nuveen, Llc | 0.00% | 88,796 | $1,956,176 | $1,139,253 | -$816,923 | -41.76% | |
| Avidity Partners Management Lp | 0.28% | 80,000 | $1,762,400 | $1,026,400 | -$736,000 | -41.76% | |
| Ghisallo Capital Management Llc | 0.03% | 75,000 | $1,652,250 | $962,250 | -$690,000 | -41.76% | |
| Rock Springs Capital Management Lp | 0.07% | 65,000 | $1,431,950 | $833,950 | -$598,000 | -41.76% | |
| Alliancebernstein L.P. | 0.00% | 61,090 | $1,345,813 | $783,785 | -$562,028 | -41.76% | |
| Rhumbline Advisers | 0.00% | 58,387 | $1,286,257 | $749,105 | -$537,152 | -41.76% | |
| Morgan Stanley | 0.00% | 57,786 | $1,273,027 | $741,394 | -$531,633 | -41.76% | |
| Bank Of America Corp | 0.00% | 56,510 | $1,244,915 | $725,023 | -$519,892 | -41.76% | |
| Russell Investments Group, Ltd. | 0.00% | 53,317 | $1,174,572 | $684,057 | -$490,515 | -41.76% | |
| Xtx Topco Ltd | 0.01% | 49,224 | $1,084,405 | $631,544 | -$452,861 | -41.76% | |
| Lazard Asset Management Llc | 0.00% | 48,391 | $1,066,054 | $620,857 | -$445,197 | -41.76% |
Frequently asked questions about KLRA
Who owns the most KLRA stock?
The largest holders of KLRA are typically major institutional investors such as asset managers and hedge funds reporting on Form 13F. The table above ranks tracked superinvestors by reported position size using the latest available filings for Kailera Therapeutics, Inc. (KLRA).
Is KLRA widely held by superinvestors?
Many widely followed stocks like KLRA appear across numerous superinvestor portfolios because of liquidity, index inclusion, and fundamentals. The holder count and table above show how broadly KLRA is represented among the institutional managers we track.
What do “Current Estimated Value”, “Gain/loss Since Filing”, and “Estimated Portfolio Performance” mean?
Current Estimated Value is reported share quantity from the latest 13F times our most recent split-adjusted U.S. session close. Gain/loss Since Filing is that estimate minus the reported 13F dollar value; Estimated Portfolio Performance is that difference as a percent of the reported value. Green means the estimate is above the filing value; red means below (not purchase cost). If many filers share the same implied filing price per share, the performance % may match across rows. These are not official fund marks or live quotes.